Modalis Therapeutics Corporation
Stock Price Chart
2026/09/30 18:46 UpdatedPrice Trend
2026/09/30 18:46 UpdatedPrice & Trading Details
2026/09/30 18:46 UpdatedPRICE
TRADING
Earnings Calendar
Updated 2026/09/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2023/11/06 | ¥-14.50 | ¥-17.59 | -21.3% |
| 2023/08/06 | ¥-10.07 | ¥-16.84 | -67.2% |
| 2023/02/12 | ¥12.36 | ¥-47.81 | -486.8% |
| 2022/11/07 | ¥-17.21 | ¥-18.34 | -6.6% |
Shareholder Composition
Updated 2026/09/01Financial Performance
2026/09/27 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | |
|---|---|
| Income Statement | |
| Revenue | ¥41M |
| Gross Profit | - |
| Operating Income | -¥2,063M |
| Pretax Income | -¥2,702M |
| Net Income | -¥2,703M |
| EPS | -¥92.85 |
| Operating Margin | -5,094.31% |
| Balance Sheet | |
| Total Assets | ¥3,130M |
| Total Equity | ¥2,941M |
| Total Liabilities | ¥189M |
| Cash | ¥2,933M |
| Interest-bearing Debt | ¥0M |
| Equity Ratio | 93.97% |
| D/E Ratio | 0.00 |
| Cash Flow | |
| Operating CF | -¥1,896M |
| Investing CF | -¥186M |
| Financing CF | ¥64M |
| Free CF | -¥2,093M |
| Efficiency | |
| ROE | -91.89% |
| ROA | -86.35% |
Latest IR Information
-
Notice Regarding Large-Scale Exercise and Monthly Exercise Status of the 19th Stock Acquisition Rights Issued by Third-Party Allotment (with Exercise Price Adjustment Clause)
Announcement of a large-scale exercise of stock acquisition rights and disclosure of monthly and cumulative exercise status. Total issued units are 240,000; the recent large-scale exercise was 26,700 units (11.1%), and monthly exercise amounted to 71,700 units (29.9%). Unexercised rights...
Read more -
Notice of Large-Scale Exercise of the 19th Warrant with Exercise Price Adjustment Clauses Issued through Third-Party Allotment
4,500,000 shares issued since the beginning of the month, 45,000 warrants exercised by September 10. Unexercised rights count to 93,700 (9,370,000 shares). Total number of issued warrants is 240,000, and the number of issued shares as of the previous fiscal...
Read more -
Notice of Monthly Exercise Status for the 19th Stock Acquisition Rights Issued under Third-Party Allocation (with Exercise Price Adjustment Provisions)
Public disclosure of the August exercise status for stock options (19th issue with exercise price adjustment provisions). For the target month, 2,090,000 shares were issued, 20,900 options were exercised, accounting for 8.7% of the total issued shares. Unexercised options at...
Read more -
[Modalis] 2026 December Term Interim Period Financial Results Briefing Materials | Including Revisions
In the second quarter of the 2026 fiscal year, cash position improved while liabilities increased, with a policy to continue R&D investments. The financial statements show changes in current assets, current liabilities, and net assets, with trends in equity ratio...
Read more -
Interim Financial Results for the Fiscal Year Ending December 2026
Interim financial results for the six months ended December 2026 have been disclosed. Includes key indicators such as consolidated net sales and net income, financial position, dividend information, and cash flow, with details on performance and financial status for the...
Read more
Latest News (5 items)
Company Information
About
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM an epigenome editing technology that combines dCas9. It also develops various therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was incorporated in 2016 and is headquartered in Chuo, Japan.
